4//SEC Filing
Novak Rodger 4
Accession 0001209191-20-054650
CIK 0001674416other
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 4:44 PM ET
Size
14.3 KB
Accession
0001209191-20-054650
Insider Transaction Report
Form 4
Novak Rodger
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Shares
2020-10-08$14.43/sh+22,238$320,894→ 670,245 total - Sale
Common Shares
2020-10-09$100.00/sh−2,762$276,200→ 648,007 total - Exercise/Conversion
Common Shares
2020-10-09$14.43/sh+2,762$39,856→ 650,769 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-10-09−2,762→ 190,315 totalExercise: $14.43Exp: 2027-06-15→ Common Shares (2,762 underlying) - Sale
Common Shares
2020-10-08$100.00/sh−22,238$2,223,800→ 648,007 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-10-08−22,238→ 193,077 totalExercise: $14.43Exp: 2027-06-15→ Common Shares (22,238 underlying)
Footnotes (2)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001682017
Filing Metadata
- Form type
- 4
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 4:44 PM ET
- Size
- 14.3 KB